ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Cyclerion Therapeutics, Inc.
31.91
+7.35
29.91%
盤後:
31.19
-0.7150
-2.24%
19:30 EDT
成交量:
11.41萬
成交額:
346.43萬
市值:
14.52億
市盈率:
-2.63
高:
32.12
開:
25.22
低:
25.22
收:
24.56
52周最高:
59.36
52周最低:
7.19
股本:
4,550.00萬
流通股本:
4,504.23萬
量比:
3.56
換手率:
0.25%
股息:
- -
股息率:
- -
每股收益(TTM):
-12.1293
每股收益(LYR):
-7.7700
淨資產收益率:
--
總資產收益率:
--
市淨率:
--
市盈率(LYR):
-4.11
資料載入中...
總覽
公司
新聞
公告
公司資料
公司名字:
Cyclerion Therapeutics, Inc.
交易所:
NASDAQ
成立時間:
2024
員工人數:
- -
公司地址:
221 Crescent Street,Building 23,Suite 105,Waltham,Massachusetts,United States
官網:
http://www.cyclerion.com
郵編:
02453
電話:
(781) 516-2325
傳真:
- -
簡介:
Cyclerion Therapeutics, Inc.於2018年9月6日在馬薩諸塞州註冊成立。Cyclerion是一家生物製藥公司,專註於在中樞神經系統和外周使用新型可溶性鳥苷酸環化酶刺激劑治療嚴重疾病。一氧化氮sGC環鳥苷一磷酸信號通路是精確控制全身生理關鍵方面的根本機制。NO-SGC-cGMP通路調節CNS和外周的多種關鍵生物學功能,已成功地被幾種藥物靶向。
董事
名稱
職位
Jonathan Violin
Chief Executive Officer and Director and President
Andrew Gottesdiener
Director
Heidi Henson
Director
Michelle Pernice
Director
Nimish Shah
Director
Tomas Kiselak
Director
股東
名稱
職位
Jonathan Violin
Chief Executive Officer and Director and President
Mark Vignola
Chief Financial Officer
Madelyn Zeylikman
General Counsel and Secretary
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/KRSA/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KRSA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KRSA\",,,,,undefined,":{"symbol":"KRSA","market":"US","secType":"STK","nameCN":"Cyclerion Therapeutics, Inc.","latestPrice":31.905,"timestamp":1789156800000,"preClose":24.56,"halted":0,"volume":114119,"hourTrading":{"tag":"盘后","latestPrice":31.19,"preClose":31.905,"latestTime":"19:30 EDT","volume":1031,"amount":32421.05,"timestamp":1789169406451,"change":-0.715,"changeRate":-0.02241,"amplitude":0.02241},"delay":0,"changeRate":0.29906351791530955,"floatShares":45042270,"shares":45500000,"eps":-12.129334,"marketStatus":"休市中","change":7.345,"latestTime":"09-11 16:00:00 EDT","open":25.22,"high":32.12,"low":25.22,"amount":3464251.9399530003,"amplitude":0.280945,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-12.129334,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":24.56,"preHourTrading":{"tag":"盘前","latestPrice":24.56,"preClose":24.56,"latestTime":"09:20 EDT","volume":159,"amount":3872.700036,"timestamp":1789132809508,"change":0,"changeRate":0,"amplitude":0.022801},"postHourTrading":{"tag":"盘后","latestPrice":31.19,"preClose":31.905,"latestTime":"19:30 EDT","volume":1031,"amount":32421.05,"timestamp":1789169406451,"change":-0.715,"changeRate":-0.02241,"amplitude":0.02241},"volumeRatio":3.5624336442143325},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KRSA\",,,,,undefined,":{"symbol":"KRSA","floatShares":45042270,"roa":"--","roe":"--","lyrEps":-7.77,"volumeRatio":3.5624336442143325,"shares":45500000,"dividePrice":0,"high":32.12,"amplitude":0.280945,"preClose":24.56,"low":25.22,"week52Low":7.1862,"pbRate":"--","week52High":59.36,"institutionHeld":0,"latestPrice":31.905,"eps":-12.129334,"divideRate":0,"volume":114119,"delay":0,"ttmEps":-12.129334,"open":25.22,"prevYearClose":8.89,"prevWeekClose":29.75,"prevMonthClose":25.76,"prevQuarterClose":23.73,"fiveDayClose":34.72,"twentyDayClose":27.37,"sixtyDayClose":22.26},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KRSA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-09-09","symbol":"KRSA","defaultRemindTime":1788960600000,"type":"split","dateTimestamp":1788926400000,"forFactor":7,"toFactor":1,"ratio":7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KRSA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KRSA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1789099200000},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1966002000,"yearFounded":2024,"address":"221 Crescent Street,Building 23,Suite 105,Waltham,Massachusetts,United States","zipCode":"02453","officePhone":"(781) 516-2325"},"stockCompanyDetail":{"websiteUrl":"http://www.cyclerion.com","stockEarnings":[{"period":"1week","weight":-0.2926},{"period":"1month","weight":-0.0172},{"period":"3month","weight":0.0796},{"period":"6month","weight":1.4197},{"period":"1year","weight":0.485},{"period":"ytd","weight":1.7627}],"compareEarnings":[{"period":"1week","weight":-0.0198},{"period":"1month","weight":-0.0165},{"period":"3month","weight":0.0217},{"period":"6month","weight":0.1443},{"period":"1year","weight":0.1619},{"period":"ytd","weight":0.1113}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Cyclerion Therapeutics, Inc.於2018年9月6日在馬薩諸塞州註冊成立。Cyclerion是一家生物製藥公司,專註於在中樞神經系統和外周使用新型可溶性鳥苷酸環化酶刺激劑治療嚴重疾病。一氧化氮sGC環鳥苷一磷酸信號通路是精確控制全身生理關鍵方面的根本機制。NO-SGC-cGMP通路調節CNS和外周的多種關鍵生物學功能,已成功地被幾種藥物靶向。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.030269},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.005726},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.111354},{"month":4,"riseRate":0.428571,"avgChangeRate":0.134458},{"month":5,"riseRate":0.25,"avgChangeRate":-0.02829},{"month":6,"riseRate":0.5,"avgChangeRate":0.038893},{"month":7,"riseRate":0.375,"avgChangeRate":0.026358},{"month":8,"riseRate":0.625,"avgChangeRate":0.100342},{"month":9,"riseRate":0.25,"avgChangeRate":-0.023924},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.324291},{"month":11,"riseRate":0.285714,"avgChangeRate":0.0186},{"month":12,"riseRate":0.428571,"avgChangeRate":0.106805}],"exchange":"NASDAQ","name":"Cyclerion Therapeutics, Inc.","nameEN":"Cyclerion Therapeutics, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"KRSA\",market:\"US\",,,undefined,":{"directors":[{"name":"Jonathan Violin","position":"Chief Executive Officer and Director and President"},{"name":"Andrew Gottesdiener","position":"Director"},{"name":"Heidi Henson","position":"Director"},{"name":"Michelle Pernice","position":"Director"},{"name":"Nimish Shah","position":"Director"},{"name":"Tomas Kiselak","position":"Director"}],"executives":[{"name":"Jonathan Violin","position":"Chief Executive Officer and Director and President"},{"name":"Mark Vignola","position":"Chief Financial Officer"},{"name":"Madelyn Zeylikman","position":"General Counsel and Secretary"}]}}}